7月14日,科济药业宣布其欧洲专利EP3445407在欧洲专利局(European Patent Office, EPO)的异议程序中取得了积极成果。该专利涉及科济药业自主研发的靶向GPC3 CAR-T细胞治疗技术。据科济药业披露,2025年7月3日,来自美国的一家生物技术公司——作为两位原始异议人中唯一提起上诉的一方——已正式撤回其对EPO异议部门决定的上诉。根据EPO相关规定,该上诉的撤回使得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.